MIPI Calculator (Mantle Cell Lymphoma International Prognostic Index)

Combine age, ECOG performance status, LDH relative to the upper limit of normal, and white blood cell count into the MIPI score and risk group used for mantle cell lymphoma.

Quick Facts

Formula
0.03535 x age + 0.6978 (ECOG>=2) + 1.367 x log10(LDH/ULN) + 0.9393 x log10(WBC)
Continuous score from Hoster et al. 2008, derived from a randomized mantle cell lymphoma trial cohort.
Risk groups
Low <5.7, Intermediate 5.7-6.2, High >=6.2
Cut-points defined in the original MIPI derivation and validation cohort.

Your Results

Calculated
MIPI score
-
Continuous prognostic score
Risk group
-
Low / Intermediate / High
LDH ratio
-
Serum LDH / upper limit of normal
Median overall survival
-
Original validation cohort

Ready

Enter the four baseline values, then calculate the MIPI score.

About the MIPI score

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a prognostic score published by Hoster and colleagues in 2008, derived from a randomized clinical trial cohort of patients with mantle cell lymphoma (MCL). It combines four variables that are routinely available at diagnosis - age, ECOG performance status, serum lactate dehydrogenase (LDH), and white blood cell (WBC) count - into a single continuous score that separates patients into three risk groups with different expected survival.

How the score is built

The MIPI score sums four weighted terms:

  • Age: 0.03535 points for every year of age.
  • ECOG performance status: 0.6978 points if performance status is 2, 3, or 4; 0 points if it is 0 or 1.
  • Lactate dehydrogenase: 1.367 x log10(LDH / upper limit of normal) - the formula uses the ratio of the patient's LDH to the local laboratory's upper limit of normal (ULN), not the raw LDH value.
  • White blood cell count: 0.9393 x log10(WBC), where WBC is expressed in x10^9/L (equivalent to thousands of cells per microliter).

Adding the four terms gives the continuous MIPI score, typically a number in roughly the 3 to 11 range.

Interpreting the result

In the cohort used to derive and validate the index, a score below 5.7 defined low risk, 5.7 up to 6.2 defined intermediate risk, and 6.2 or higher defined high risk. About 44% of patients fell into the low-risk group (median overall survival not reached, roughly 60% alive at 5 years), 35% into intermediate risk (median overall survival about 51 months), and 21% into high risk (median overall survival about 29 months). These figures describe the original study population and are not a prediction for any one patient.

When to consult a professional

This tool performs the published MIPI arithmetic for education and record-keeping. It does not diagnose mantle cell lymphoma and does not recommend treatment. Staging, prognosis discussions, and treatment decisions should be made with a hematologist-oncologist who can interpret the score alongside biopsy findings, imaging, the Ki-67 proliferation index, and the full clinical picture.

Frequently Asked Questions

What is the MIPI score and what does it measure?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a prognostic score for adults with mantle cell lymphoma. It combines age, ECOG performance status, serum LDH relative to the local upper limit of normal, and white blood cell count into a single continuous score that groups patients into low, intermediate, and high risk categories.
How is the MIPI score calculated?
The formula is 0.03535 x age (years), plus 0.6978 if ECOG performance status is 2 or higher (0 otherwise), plus 1.367 x log10(LDH / upper limit of normal), plus 0.9393 x log10(white blood cell count in x10^9/L). The four weighted terms are added together to produce the continuous MIPI score.
What do the MIPI risk groups mean?
In the original validation cohort, a score below 5.7 was low risk (median overall survival not reached, roughly 60% alive at 5 years), 5.7 up to 6.2 was intermediate risk (median overall survival about 51 months), and 6.2 or higher was high risk (median overall survival about 29 months). These are population-level estimates from that cohort, not an individual prognosis.

Related calculators